Total number of shares and voting rights in Zealand Pharma at September 30, 2022
Zealand Pharma announced the total number of shares and voting rights as of September 30, 2022, following changes in its share capital due to employee warrants exercised. The total number of shares is 46,538,186, which reflects the nominal value of DKK 1 each. This disclosure aligns with the Danish Capital Markets Act requirements for transparency in shareholder equity. Zealand Pharma focuses on developing peptide-based medicines and maintains partnerships with Boehringer Ingelheim and AstraZeneca.
- Total shares increased to 46,538,186, indicating active employee participation.
- Continued focus on innovative peptide-based medicines with ongoing clinical development.
- None.
Company announcement – No. 42 / 2022
Total number of shares and voting rights in Zealand Pharma at September 30, 2022
Copenhagen, DK and Boston, MA, September 30, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.
In Company announcement No. 39/2022 from September 13, 2022, Zealand announced an increase in share capital relating to exercise of employee warrants. Following this announcement, the table below lists the total number of shares and voting rights in Zealand up to and including September 30, 2022.
Date | Number of shares (nominal value of DKK 1 each) | Share capital (nominal value in DKK) | Number of voting rights |
| August 31, 2022 | 46,538,186 | 46,538,186 | 46,538,186 |
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.
Forward-Looking Statement
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events, including forward-looking statements about the termination of the Company’s ADR program. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly.
Contact:
| Anna Krassowska, PhD Vice President, Investor Relations & Corporate Communications Zealand Pharma Email: ank@zealandpharma.com David Rosen (U.S. Media) Argot Partners Email: media@zealandpharma.com |
FAQ
What is the total number of shares for Zealand Pharma as of September 30, 2022?
How many voting rights does Zealand Pharma have as of September 30, 2022?
What changes occurred in Zealand Pharma's share capital recently?
Which companies has Zealand Pharma partnered with?
